Vaccinate your child and save its grandparents from a heart attack? Current perspectives in antipneumococcal vaccination

Journal of Internal Medicine

Volumn 266, Issue 5, 2009, Pages 432-444

  Vila Córcoles, Angel ^a  

^a INSTITUT CATALÀ DE LA SALUT   (Spain)

Author keywords

Myocardial infarction; Pneumococcal vaccine; Pneumonia

Indexed keywords

PNEUMOCOCCUS VACCINE;

CHILD; CLINICAL TRIAL; DRUG EFFICACY; HEART INFARCTION; HUMAN; MORBIDITY; MORTALITY; PREVENTION AND CONTROL; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINES, CONJUGATE;

EID: 70349847662     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2009.02149.x     Document Type: Review

References (69)

1. Ortqvist A, Hedlund J, Kalin M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin Respir Crit Care Med 2005 26 : 563 574.
2. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005 5 : 83 93.
3. Fedson DS. Pneumococcal vaccination for older adults: the first 20 years. Drugs Aging 1999 15 (Suppl 1 21 30.
4. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practice (ACIP). MMWR Recomm Rep 1997 46 (RR-8 1 24.
5. Bogaert D, Hermans PW, Adrian PV, Rumke HC, de Groot R. Pneumococcal vaccines: an update on current strategies. Vaccine 2004 22 : 2209 2220.
6. Vila-Corcoles A. Advances in pneumococcal vaccines: what are the advantages for the elderly? Drugs Aging 2007 24 : 791 800.
7. Fedson DS, Musher DM. Pneumococcal polysaccharide vaccine. In : Plotkin SA, Orenstein WA, eds Vaccines, 4th edn. Philadelphia : Saunders, 2003 529 588.
8. Sankilampi U, Honkanen PO, Bloigu A, Herva E, Leinonen M. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1996 173 : 387 393. (Pubitemid 26042439)
9. Artz AS, Ershler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev 2003 16 : 308 318.
10. Fine MJ, Smith MA, Carson CA et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994 154 : 2666 2677.
11. Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 2001 19 : 4780 4790.
12. Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis 2003 3 : 71 8.
13. Watson L, Wilson BJ, Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 2002 20 : 2166 2173.
14. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: comparison of meta-analyses. Eur J Epidemiol 2004 19 : 353 363. (Pubitemid 39005435)
15. Conaty S, Watson L, Dinnes J, Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine 2004 22 : 3214 3224.
16. Fedson DS, Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 2004 22 : 927 946.
17. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009 180 : 48 58.
18. Andrews R, Moberley SA. The controversy over the efficacy of pneumococcal vaccine. CMAJ 2009 180 : 18 9.
19. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008 CD000422.
20. Sisk JE, Moskowitz AJ, Whang W et al. Cost- effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997 278 : 1333 1339.
21. Evers SM, Ament AJ, Colombo GL et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis 2007 26 : 531 540.
22. Vila-Corcoles A. Is the pneumococcal polysaccharide vaccine effective in preventing pneumonia? Lancet Infect Dis 2008 8 : 405 406.
23. Kaufman P. Pneumonia in old age: active immunization against pneumonia with pneumococcus polysaccharide: results of a six year study. Arch Intern Med 1947 79 : 518 531.
24. Riley ID, Tarr PI, Andrews M et al. Immunisation with a polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community. Lancet 1977 1 : 1338 1341.
25. Vila-Corcoles A, Salsench E, Rodriguez-Blanco T et al. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine 2009 27 : 1504 1510.
26. Musher DM, Rueda-Jaimes AM, Graviss EA, Rodriguez-Barradas MC. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia. Clin Infect Dis 2006 43 : 1004 1008.
27. Roson B, Fernandez-Sabe N, Carratala J et al. Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. Clin Infect Dis 2004 38 : 222 226.
28. Stralin K, Kaltoft MS, Konradsen HB, Olcén P, Holmberg H. Comparison of two urinary antigen tests for establishment of pneumococcal etiology of adult community-acquired pneumonia. J Clin Microbiol 2004 42 : 3620 3625.
29. Leeming JP, Cartwright K, Morris R, Martin SA, Smith MD, South-West Pneumococcus Study Group. Diagnosis of invasive pneumococcal infection by serotype-specific urinary antigen detection. J Clin Microbiol 2005 43 : 4972 4976.
30. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005 352 : 1685 1695.
31. Madjid M, Miller CC, Zarubaev VV et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy- confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J 2007 28 : 1205 1210.
32. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004 351 : 2611 2618.
33. Ramirez J, Aliberti S, Mirsaeidi M et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis 2008 47 : 182 187.
34. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007 45 : 158 165.
35. Corrales Medina VF, Gore M, Serpa J, Dakik H, Fatemi O, Musher M. Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. The 46th Infectious Disease Society of America Annual Meeting, Washington DC, USA, October 25-28, 2008. Abstract 671.
36. Lamontagne F, Garant MP, Carvalho JC, Lanthier L, Smieja M, Pilon D. Pneumococcal vaccination and risk of myocardial infarction. CMAJ 2008 179 : 773 777.
37. Madjid M. Acute infections, vaccination and prevention of cardiovascular disease. CMAJ 2008 179 : 749 750.
38. Skowronski DM, Janjua NZ, Hottes TS, Patrick DM, De Serres G. Pneumococcal vaccination and myocardial infarction. CMAJ 2009 180 : 319 author reply 20.
39. Binder CJ, Horkko S, Dewan A et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between streptococcus pneumoniae and oxidized LDL. Nat Med 2003 9 : 736 743.
40. Ridker PM, Danielson E, Fonseca FA et al., JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008 359 : 2195 2207.
41. Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 2006 42 : 1093 1101.
42. Black S, Shinefield H, Fireman B et al. The Northern California Kaiser Permanente Vaccine Study Center Group. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000 19 : 187 195.
43. Eskola J, Kilpi T, Palmu A et al., Finnish Otitis Media Study Group. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001 344 : 403 409. (Pubitemid 32128672)
44. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005 54 : 893 897.
45. Lexau CA, Lynfield R, Danila R et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005 294 : 2043 2051.
46. Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction - eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008 57 : 144 148.
47. Hicks L, Harrison L, Flannery B et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007 196 : 1346 1354.
48. Centers for Disease Control and Prevention. Progress in introduction of pneumococcal conjugate vaccine worldwide, 2000 - 2008. MMWR Morb Mortal Wkly Rep 2008 57 : 1148 1151.
49. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance System. Available at: http://www.cdc.gov/vaccines/recs/acip/ downloads/mtg-slides-jun08/03-1-pneu.pdf.Accessed 13 May 2009.
50. Fry AM, Zell ER, Schuchat A, Butler JC, Whitney CG. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine 2002 21 : 303 311.
51. Lockhart SP, Hackell JG, Fritzell B. Pneumococcal conjugate vaccines: emerging clinical information and its implications. Expert Rev Vaccines 2006 5 : 553 564.
52. Abraham-Van Parijs B. Review of pneumococcal conjugate vaccine in adults: implications on clinical development. Vaccine 2004 22 : 1362 1371.
53. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007 7 : 597 606.
54. De Roux A, Schmoele-Thoma B, Siber GR et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008 46 : 1015 1023.
55. Lesprit P, Pedrono G, Molina JM et al. ANRS114-Pneumovac Study Group. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007 21 : 2425 2434.
56. Chan CY, Molrine DC, George S et al. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis 1996 173 : 256 258.
57. Lucero MG, Dulalia VE, Parreno RN et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age. Cochrane Database Syst Rev 2004 CD004977.
58. Cutts FT, Zaman SM, Enwere G et al., Gambian Pneumococcal Vaccine Trial Group. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005 365 : 1139 1146. (Pubitemid 40417563)
59. Feikin DR, Klugman KP, Facklam RR et al. Increased prevalence of pediatric pneumococcal serotypes in elderly adults. Clin Infect Dis 2005 41 : 481 487.
60. Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 2008 47 : 1328 1338.
61. WHO. Health Canada Consultation on serological criteria for evaluation and licensing of new pneumococcal vaccines, Ottawa, Canada. 7-8 July 2008. Available at: http://www.who.int/biologicals/publications/meetings/areas/ vaccines/pneumococcal/Executive%20Summary%20FINAL%20version%205%20pneumo%2030- July-08%20-2-.pdf.
62. Hak E, Sanders EA, Verheij TJ et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008 66 : 378 383.
63. Briles DE. Protection of the elderly from pneumococcal pneumonia with a protein-based vaccine? Mech Ageing Dev 2004 125 : 129 131.
64. Tai SS. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol 2006 32 : 139 153.
65. Orihuela CJ, Gao G, Francis KP, Yu J, Tuomanen EI. Tissue-specific contributions of pneumococcal virulence factors to pathogenesis. J Infect Dis 2004 190 : 1661 1669.
66. Ogunniyi AD, Grabowicz M, Briles DE, Cook J, Paton JC. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun 2007 75 : 350 357.
67. Giefing C, Meinke AL, Hanner M et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J Exp Med 2008 205 : 117 131.
68. Wright AK, Briles DE, Metzger DW, Gordon SB. Prospects for use of interleukin-12 as a mucosal adjuvant for vaccination of humans to protect against respiratory pneumococcal infection. Vaccine 2008 26 : 4893 4903.
69. Wuorimaa T, Dagan R, Väkeväinen M et al. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J Infect Dis 2001 184 : 1211 1215.